Skin-Applied Melanoma Peptide Vaccine Triggers Strong Immune Response in 83-86% of Patients

Twenty-eight melanoma patients were randomized to four adjuvant groups for transdermal peptide vaccination (12 melanoma peptides + tetanus helper peptide + GM-CSF). CD8+ T cell responses to transdermal vaccination in DMSO occurred in 83% (group 3) and 86% (group 4) of participants, dramatically exceeding responses with IFA: 29% (group 1) and 14% (group 2). CD4+ T cell responses to tetanus peptide occurred in 61% overall, with large durable responses in DMSO groups. However, 5/7 patients receiving DMSO + imiquimod developed severe rash, one dose-limiting. Ten-year overall survival was 67% and disease-free survival was 44%.

Phase I/II randomized clinical trial in 28 melanoma patients across four adjuvant groups. Peptides applied topically on days 1, 8, and 15, then injected intradermally/subcutaneously every 3 weeks for 6 cycles. Immune responses measured by ELIspot assay for CD8+ and CD4+ T cell responses. Toxicities recorded and 10-year survival outcomes tracked.

This trial proves that cancer peptide vaccines can be delivered through the skin, achieving far higher immune response rates than traditional injection methods. If validated in larger trials, transdermal vaccination could make cancer immunization less invasive, more effective, and more accessible — potentially transforming how therapeutic cancer vaccines are administered.

Peptide-based cancer vaccines have shown immunogenicity in many trials but have struggled with clinical efficacy, partly due to suboptimal delivery. This study suggests the delivery method matters enormously — targeting skin Langerhans cells via transdermal application may unlock the potential that injectable peptide vaccines have not fully realized. Combined with the checkpoint immunotherapy revolution, improved peptide vaccination could become a powerful combination approach.

Small trial (n=28) without an unvaccinated control group. The 10-year survival cannot be directly attributed to vaccination. Imiquimod caused unacceptable toxicity in most recipients. The DMSO delivery mechanism needs further pharmacokinetic characterization. The trial enrolled patients across a range of melanoma stages, and the small group sizes limit statistical comparisons between adjuvants.